Abstract
The complement system is a major component of the innate defence of animals against invading microorganisms, and is also essential for the recognition and clearance of damaged or structurally-altered host cells or macromolecules. The system is activated by three different pathways, each of which responds, using different recognition molecules, to a very wide range of activators. The recognition protein of the complement classical pathway, C1q is described in detail here, with comparisons to the alternative pathway.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344:1058–1066.
Walport MJ. Complement. Second of two parts. N Engl J Med 2001; 344:1140–1144.
Mayilyan KR, Kang YH, Dodds AW et al. The complement system in innate immunity. In: Heine H, ed. Innate Immunity of Plants, Animals and Humans (Nucleic acids and molecular biology vol 21). Heidelberg: Springer, 2008:219–236.
Sim RB, Dodds AW The complement system: an introduction. In Dodds AW, Sim RB, eds. Complement, a Practical Approach. Oxford: Oxford University Press, 1997:1–18.
Sim RB, Reid KBM. C1: Molecular interaction with activating systems. Immunol Today 1991; 12:307–311.
Sim RB, Malhotra R. Interactions of carbohydrates and lectins with complement. Biochem Soc Trans 1994; 22:106–111.
Dodds AW, Sim RB, Porter RR et al. Activation of the first component of human complement (C1) by antibody-antigen aggregates. Biochem J 1978; 175:383–390.
Krarup A, Mitchell DA, Sim RB. Recognition of acetylated oligosaccharides by human L-ficolin. Immunol Lett 2008; 118:52–56.
Sim RB, Tsiftsoglou SA. Proteases of the complement system. Biochem Soc Trans 2004; 32:21–27.
Kemper C, Hourcade DE. Properdin: New roles in pattern recognition and target clearance. Mol Immunol 2008; 45:4048–4056.
Sim RB, Moffatt BE, Shaw JM et al. Complement control proteins and receptors: from FH to CR4. In: Reid KB, Sim RB, eds. Molecular Aspects of Innate and Adaptive Immunity. Cambridge: Royal Society of Chemistry, 2008:84–104.
Reid KB, Porter RR. Subunit composition and structure of subcomponent C1q of the first component of human complement. Biochem J 1976, 155:19–23.
Knobel HR, Villiger W, Isliker H. Chemical analysis and electron microscopy studies of human C1q prepared by different methods. Eur J Immunol 1975; 5:78–82.
Reid KB, Sim RB, Faiers AP. Inhibition of the reconstitution of the haemolytic activity of the rirst component of human complement by a pepsin-derived fragment of subcomponent C1q. Biochem J 1977; 161:239–245.
Sim RB, Arlaud GJ, Colomb MG. C1-inhibitor-dependent dissociation of human complement component C1 bound to immune complexes. Biochem J 1979; 179:449–457.
Sim RB, Arlaud GJ, Colomb MG. Kinetics of reaction of human C1-inhibitor with the human complement system proteases C1r and C1s. Biochim Biophys Acta 1980; 612:433–449.
Colten HR, Gordon JM, Borsos T et al. Synthesis of the first component of human complement in vitro. J Exp Med 1968; 128:595–603.
Morris KM, Colten HR, Bing DH. The first component of complement. A quantitative comparison of its biosynthesis in culture by human epithelial and mesenchymal cells. J Exp Med 1978; 148:1007–1014.
Schwaeble W, Schafer MK, Petry F et al. Follicular dendritic cells, interdigitaring cells, and cells of the monocyte-macrophage lineage are the C1q-producing sources in the spleen. Identification of specific cell types by in situ hybridization and immunohistochemical analysis. J Immunol 1995; 155:4971–4977.
Whaley K. Biosynthesis of the complement components and the regulatory proteins of the alternative complement pathway by human peripheral blood monocytes. J Exp Med 1980; 151:501–514.
Gulati P, Lemercier C, Guc D et al. Regulation of the synthesis of C1 subcomponents and C1-inhibitor. Behring Inst Mitt 1993; 93:196–203.
Tseng Y, Zavodszky P, Schumaker VN. The human complement C1 complex has a picomolar dissociation constant at room temperature. J Immunol 1997; 158:937–944.
Schumaker VN, Zavodszky P, Poon PH. Activation of the first component of complement. Annu Rev Immunol 1987; 5:21–42.
Bindon CI, Hale G, Waldmann H. Complement activation by immunoglobulin does not depend solely on C1q binding. Eur J Immunol 1990; 20:277–281.
Bindon CI, Hale G, Waldmann H. Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies. Eur J Immunol 1988;18:1507–1514.
Brüggemann M, Williams GT, Bindon CI et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 1987;166:1351–1361.
Sim RB ed. Activators and Inhibitors of Complement. Dordrecht: Kluwer, 1993.
Roumenina L, Bureeva S, Kantardjiev A et al. Complement C1q-target proteins recognition is inhibited by electric moment effectors. J Mol Recognit 2007; 20:405–415.
Arnold JN, Wormald MR, Sim RB et al. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 2007; 25:21–50.
Duncan AR, Winter G. The binding site for C1q on IgG. Nature 1988; 332:738–742.
Idusogie EE, Presta LG, Gazzano-Santoro H et al. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol 2000; 164:4178–4184.
Perkins S J, Nealis AS, Sutton BJ et al. Solution structure of human and mouse immunoglobulin M by synchrotron X-ray scattering and molecular graphics modelling. A possible mechanism for complement activation. J Mol Biol 1991; 221:1345–1366.
Païdassi H, Tacnet-Delorme P, Lunardi T et al. The lectin-like activity of human C1q and its implication in DNA and apoptotic cell recognition. FEBS Lett 2008; 582:3111–3116.
Loos M, Bitter-Suermann D, Dierich MP. Interaction of the first (C1), the second (C2) and the fourth (C4) component of complement with different preparations of bacterial lipopolysaccharides and with lipid A. J Immunol 1974; 112:935–950.
Zohair A, Chesne S, Wade RH et al. Interaction between complement subcomponent C1q and bacterial lipopolysaccharides. Biochem J 1989; 257:865–873.
Latsch M, Möllerfeld J, Ringsdorf H et al. Studies on the interaction of C1q, a subcomponent of the first component of complement, with porins from Salmonella minnesota incorporated into artificial membranes. FEBS Lett 1990; 276:201–204.
Van Schravendijk MR, Dwek RA. Interaction of C1q with DNA. Mol Immunol 1982; 19:1179–1184.
Kovacsovics T, Tschopp J, Kress A et al. Antibody-independent activation of C1, the first component of complement, by cardiolipin. J Immunol 1985; 135:2695–2703.
Tan LA, Sim RB. Complement activation by phospholipids (PL). Mol Immunol 2001; 38:122–122.
Païdassi H, Tacnet-Delorme P, Garlatti V et al. C1q binds phosphatidylserine and likely acts as a multiligand-bridging molecule in apoptotic cell recognition. J Immunol 2008; 180:2329–2338.
Sorensen IJ, Nielsen EH, Andersen O et al 1996. Binding of complement proteins C1q and C4bp to serum amyloid P component (SAP) in solid contra liquid phase. Scand J Immunol 1996; 44:401–409.
McGrath FD, Brouwer MC, Arlaud GJ et al. Evidence that complement protein C1q interacts with C-reactive protein through its globular head region. J Immunol 2006; 176:2950–2957.
Agrawal A, Shrive AK, Greenhough TJ et al. Topology and structure of the C1q-binding site on C-reactive protein. J Immunol 2001; 166:3998–4004.
Bickerstaff MC, Botto M, Hutchinson WL et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 1999; 5:694–697.
Hicks PS, Saunero-Nava L, Du Clos TW et al. Serum amyloid P component binds to histories and activates the classical complement pathway. J Immunol 1992; 149:3689–3694.
Boackle RJ, Connor MH, Vesely J. High molecular weight nonimmunoglobulin salivary agglutinins (NLA) bind C1Q globular heads and have the potential to activate the first complement component. Mol Immunol 1993; 30:309–319.
Ebenbichler CF, Thielens NM, Vornhagen M et al 1991. Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J Exp Med 1991; 174:1417–1424.
Loos M, Clas F, Fischer W. Interaction of purified lipoteichoic acid with the classical complement pathway. Infect Immun 1986; 53:595–599.
Carroll MV, Lack N, Krarup A et al. Multiple routes of complement activation by mycobacterium bovis BCG. Molec Immunol 2008; 45:4168–4168.
Sim RB, Kishore U, Villiers CL et al. C1q binding and complement activation by prions and amyloids. Immunobiology 2007; 212:355–362.
Salvador-Morales C, Flahaut E, Sim E et al. Carbon nanotubes activate the human serum complement system. Molec Immunol 2006; 43:193–201.
Nilsson UR, Lam O, Nilsson B et al. Modification of the complement binding properties of polystyrene: effects of end-point heparin attachment. Scand J Immunol 1993; 37:349–354.
Cliquet F, Cuillière ML, Montagne P et al. Interactions of complement fraction C1q, fibronectin, and immunoglobulin G with polyacrylic microparticles used as solid-phase in immunoassay. J Biomed Mater Res 1993; 27:587–597.
Hamad OA, Ekdahl KN, Nilsson PH et al. Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets. J Thromb Haemost 2008; 6:1413–1421.
Kirschfink M, Blase L, Engelmann S et al. Secreted chondroitin sulfate proteoglycan of human B cell lines binds to the complement protein C1q and inhibits complex formation of C1. J Immunol 1997; 158:1324–1331.
Almeda S, Rosenberg RD, Bing DH. The binding properties of human complement component C1q. Interaction with mucopolysaccharides. J Biol Chem 1983; 258:785–791.
Krumdieck R, Höök M, Rosenberg LC et al. The proteoglycan decorin binds C1q and inhibits the activity of the C1 complex. J Immunol 1992; 149:3695–3701.
Stevens B, Allen NJ, Vazquez LE, et al. The classical complement cascade mediates CNS synapse elimination. Cell 2007; 131:1164–1178.
Mayilyan KR, Weinberger DR, Sim RB. The complement system in schizophrenia. Drug News Perspect 2008; 21:200–210.
Navratil JS, Watkins SC, Wisnieski JJ et al. The globular heads of C1q specifically recognize surface blebs of apoptotic vascular endothelial cells. J Immunol 2001; 166:3231–3238.
Nauta AJ, Trouw L, Daha MR et al 2002. Direct binding of C1q to apoptotic cells and cell blebs induces complement activation. Eur J Immunol 2002; 32:1726–1732.
Ogden CA, deCathelineau A, Hoffmann PR et al 2001. C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J Exp Med 2001; 194:781–790.
Nauta AJ, Castellano G, Xu W et al. Opsonization with C1q and mannose-binding lectin targets apoptotic cells to dendritic cells. J Immunol 2004; 173:3044–3050.
Nauta AJ, Daha MR, van Kooten C et al. Recognition and clearance of apoptotic cells: a role for complement and pentraxins. Trends Immunol 2003; 24:148–153.
Pickering MC, Botto M, Taylor PR et al. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 2000; 76:227–240.
Botto M, Dell’Agnola C, Bygrave AE et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 1998; 19:56–59.
Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994; 179:1317–1324.
Gaboriaud C, Juanhuix J, Gruez A et al. The crystal structure of the globular head of complement protein C1q provides a basis for its versatile recognition properties. J Biol Chem 2003; 278:46974–46980.
Corpet F. Multiple sequence alignment with hierarchical clustering. Nucl Acids Res 1988; 16:10881–10890.
Kishore U, Strong P, Perdikoulis MV et al. A recombinant homotrimer, composed of the alpha helical neck region of human surfactant protein D and C1q B chain globular domain, is an inhibitor of the classical complement pathway. J Immunol 2001; 166:559–565.
Kishore U, Leigh LE, Eggleton P et al. Functional characterization of a recombinant form of the C-terminal, globular head region of the B-chain of human serum complement protein, C1q. Biochem J 1998; 333:27–32.
Kishore U, Gupta SK, Perdikoulis MV et al. Modular organization of the carboxyl-terminal, globular head region of human C1q A, B, and C chains. J Immunol 2003; 171:812–820.
Kojouharova MS, Gadjeva MG, Tsacheva IG et al. Mutational analyses of the recombinant globular regions of human C1q A, B, and C chains suggest an essential role for argininc and histidine residues in the C1q-IgG interaction. J Immunol 2004; 172:4351–4358.
Roumenina LT, Ruseva MM, Zlatarova A et al. Interaction of C1q with IgG1, C-reactive protein and pentraxin 3: mutational studies using recombinant globular head modules of human C1q A, B, and C chains. Biochemistry 2006; 45:4093–4104.
Gadjeva MG, Rouseva MM, Zlatarova AS et al. Interaction of Human C1q with IgG and IgM: Revisited. Biochemistry 2008; 47(49): 13093–14002.
Roumenina LT, Kantardjiev AA, Atanasov BP et al. Role of Ca2+ in the electrostatic stability and the functional activity of the globular domain of human C1q. Biochemistry 2005; 44:14097–15009.
Sim, RB, Moestrup SK, Stuart GR et al. Interaction of C1q and the collectins with the potential receptors calreticulin (cC1qR/collectin receptor) and megalin. Immunobiology 1998; 199:208–215.
Malhotra R, Thiel S, Reid KB et al. Human leukocyte C1q receptor binds other soluble proteins with collagen domains. J Exp Med 1990; 172:955–959.
Malhotra R, Laursen SB, Willis AC et al Localization of the receptor-binding site in the collectin family of proteins. Biochem J 1993; 293:15–19.
Guan E, Robinson SL, Goodman EB et al. Cell-surface protein identified on phagocytic cells modulates the C1q-mediated enhancement of phagocytosis. J Immunol 1994; 152:40054011.
McGreal E., Ikewaki N, Akatsu H et al. Human C1qRp is identical with CD93 and the mNI-11 antigen but does not bind C1q. J Immunol 2002; 168:5222–5228.
Klickstein L, Barbashov SF, Liu T et al. Complement receptor type 1 (CRI, CD35) is a receptor for C1q. Immunity 1997; 7:345–353.
van den Berg RH., Faber-Krol MC, Sim RB et al 1998. The first subcomponent of complement, C1q, triggers the production of IL-8, IL-6, and monocyte chemoattractant peptide-1 by human umbilical vein endothelial cells. J Immunol 1998; 161:6924–6931.
Dodds AW. The evolution of complement systems. In: Reid KB, Sim RB, eds. Molecular Aspects of Innate and Adaptive Immunity. Cambridge: Royal Society of Chemistry, 2008:27–48.
Matsushita M, Matsushita A, Endo Y et al. Origin of the classical complement pathway: Lamprey orthologue of mammalian C1q acts as a lectin. Proc Natl Acad Sci USA 2004; 101:10127–10131.
Yu Y, Huang H, Wang Y et al. A novel C1q family member of amphioxus was revealed to have a partial function of vertebrate C1q molecule. J Immunol 2008; 181:7024–7032.
Nolan KF, Schwaeble W, Kaluz S et al Molecular cloning of the cDNA coding for properdin, a positive regulator of the alternative pathway of human complement. Eur J Immunol 1991; 21:771–776.
Schwaeble W, Reid KB. Does properdin crosslink the cellular and the humoral immune response? Immunol Today 1999; 20:17–21.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Landes Bioscience and Springer Science+Business Media
About this chapter
Cite this chapter
Kang, YH., Tan, L.A., Carroll, M.V., Gentle, M.E., Sim, R.B. (2009). Target Pattern Recognition by Complement Proteins of the Classical and Alternative Pathways. In: Kishore, U. (eds) Target Pattern Recognition in Innate Immunity. Advances in Experimental Medicine and Biology, vol 653. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0901-5_8
Download citation
DOI: https://doi.org/10.1007/978-1-4419-0901-5_8
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-0900-8
Online ISBN: 978-1-4419-0901-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)